Press coverage about Boston Scientific (NYSE:BSX) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Boston Scientific earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 44.4300526322151 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Boston Scientific’s Cardiovascular Segment: Q1 2018 Performance (finance.yahoo.com)
- Analyst Recommendations for Boston Scientific and Peers in June (finance.yahoo.com)
- Boston Scientific’s Recent Acquisitions and What They Mean (finance.yahoo.com)
- Boston Scientific’s MedSurg Segment: Q1 2018 Performance (finance.yahoo.com)
- Boston Scientific’s Investment in Millipede (finance.yahoo.com)
BSX has been the topic of several research reports. Piper Jaffray Companies initiated coverage on Boston Scientific in a report on Friday, February 23rd. They set an “overweight” rating and a $31.00 price objective on the stock. Royal Bank of Canada reiterated a “top pick” rating and issued a $32.00 price target on shares of Boston Scientific in a report on Monday, March 5th. ValuEngine downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Wednesday, March 7th. TheStreet downgraded Boston Scientific from a “b” rating to a “c” rating in a report on Monday, March 5th. Finally, Morgan Stanley lifted their price target on Boston Scientific from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Monday, March 19th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eighteen have given a buy rating and three have given a strong buy rating to the company’s stock. Boston Scientific presently has a consensus rating of “Buy” and a consensus price target of $32.39.
Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 25th. The medical equipment provider reported $0.33 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.32 by $0.01. Boston Scientific had a return on equity of 25.10% and a net margin of 1.21%. The business had revenue of $2.38 billion during the quarter, compared to analysts’ expectations of $2.34 billion. During the same quarter in the previous year, the firm posted $0.29 EPS. The company’s revenue for the quarter was up 10.1% on a year-over-year basis. sell-side analysts anticipate that Boston Scientific will post 1.39 earnings per share for the current fiscal year.
In related news, CFO Daniel J. Brennan sold 60,209 shares of Boston Scientific stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $27.87, for a total value of $1,678,024.83. Following the completion of the transaction, the chief financial officer now owns 299,644 shares in the company, valued at approximately $8,351,078.28. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP David A. Pierce sold 1,650 shares of Boston Scientific stock in a transaction dated Thursday, June 7th. The shares were sold at an average price of $30.83, for a total value of $50,869.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 206,116 shares of company stock valued at $6,320,005. 0.73% of the stock is owned by company insiders.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.